Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odevixibat
- Development stage
- Approved
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Odevixibat is a small molecule, orally administered, reversible and selective inhibitor of the ileal bile acid transporter (IBAT), also known as the ileal sodium/bile acid cotransporter. It is indicated for the treatment of pruritus (itching) in patients with progressive familial intrahepatic cholestasis (PFIC) aged 3 months and older, and for Alagille syndrome (ALGS) in patients aged 1 year and older. By inhibiting IBAT in the distal ileum, odevixibat reduces reabsorption of bile acids from the intestine, leading to decreased serum bile acid levels and increased fecal excretion. This mechanism alleviates pruritus associated with cholestatic liver diseases. Odevixibat was developed by Albireo Pharma and approved for use in both the United States and European Union in July 2021[5][3][6].
- Brand names
- Bylvay
- Other names
- odevixibat
02
Targets
SLC10A2 (Solute carrier family 10 member 2)
Beyond the preview
Go deeper on odevixibat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odevixibat.